|Table of Contents|

The relationship between PD-1 expression and CD45RA+ and CD45RO+T cells in peripheral T cell lymphoma patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 10
Page:
1643-1646
Research Field:
Publishing date:

Info

Title:
The relationship between PD-1 expression and CD45RA+ and CD45RO+T cells in peripheral T cell lymphoma patients
Author(s):
Lv Xuewen; Chen Huanwei; Xu Qiong; Wang Bo; Li Sheng
Department of Chemotherapy,Central Hospital of Guangdong Provincial Agricultural Reclamation,Guangdong Zhanjiang 524002,China.
Keywords:
peripheral T cell lymphoma; PD-1; CHOP; naive T cells; memory T cells
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2017.10.034
Abstract:
Objective:To investigate the relationship between the expression of PD-1 in lymphoid tissue and the level of initial and memory T cells in peripheral blood in peripheral T cell lymphoma (PTCL) patients.Methods:The expression of PD-1 was detected by immunohistochemistry in lymphoma tissue in 20 PTCL patients.The proportion of CD4+CD45RA+,CD4+CD45RO+,CD8+CD45RA+ and CD8+CD45RO+T cells before and after CHOP chemotherapy in peripheral blood in 20 PTCL patients were detected by flow cytometry.The relationship between expression of PD-1 and T cell subsets was analysed.Results:The expression of PD-1 and PD-L1 protein were increased in PTCL patients,and PD-1 positive patients had poor curative effect.The CD4+T cells and CD8+T cells in PD-1 positive patients were significantly lower than that of PD-1 negative group.The CD4+CD45RO+,CD8+CD45RA+ and CD8+CD45RO+T cells in the PD-1 negative group were significantly higher than those in the PD-1 positive group,the difference was statistically significant.Conclusion:The expression of PD-1/PD-L1 protein in patients with PTCL is abnormal,and the PD-1 positive patients have more obvious defects in T cell immune function.

References:

［1］Li XQ,Li GD，Gao ZF,et al.Distribution of lymphoma subtypes in China:in 10002 cases of domestic multi center cases［J］.Theory and Practice of Diagnosis,2012,2(11):111-115.［李小秋，李甘地，高子芬,等．中国淋巴瘤亚型分布：国内多中心性病例 10002 例分析［J］．诊断学理论与实践，2012，2(11):111-115.］
［2］Yan YZ,Na K,Wei XD,et al.Research progress on the mechanism of tumor immune escape ［J］.J Fudan University (Medical Science Edition),2013,40(5):619-623.［阎永贞，那可，魏晓东,等．肿瘤免疫逃逸机制的研究进展［J］.复旦学报(医学版),2013，40(5):619-623.］
［3］Sheppard Ka,Fitz LJ,Lee JM,et al.PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKC theta［J］.Febs Lett,2004,574(1-3):37-41.］
［4］Lv XW,Xu Q,Chen HW,et al.The expression of PD-1 and PD-L1 protein in peripheral T cell lymphoma and its correlation with prognosis ［J］.Tumor Pharmacy,2016,6(1):44-48.［吕学文，徐琼，陈焕伟,等.PD-1、PD-L1蛋白在外周T细胞淋巴瘤中的表达及与预后的相关性分析［J］.肿瘤药学,2016,6(1):44-48.］
［5］Swerdlow SH，Campo E，Harris NL，et al．WHO classification of tumours of haemtopoietic and lymphoid tissues［M］．Lyon:International Agency for Research on Cancer，2008:306-308．
［6］Wu BQ,Liu YF.Immunohistochemical pathological diagnosis［M］.Beijing:Beijing Science and Technology Press,2007:25.［吴秉铨，刘彦仿.免疫组织化学病理诊断［M］.北京：北京科学技术出版社，2007:25.］
［7］Yamamoto R,Nishikori M,Kitawaki T,et al.PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma ［J］.Blood,2008,111(6):3220-3224.
［8］Iwamura K,Kato T,Miyahara Y,et al.siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions ［J］.Gene Ther,2012,19(10):959-966.
［9］Cheson BD,Pfistner B,Malik E.Revised response criteria for malignant lymphoma ［J］.2007,25:579-586.
［10］Armand P,Nagler A,Weller EA,et al.Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma:results of an international phase II trial ［J］.J Clin Oncol,2013,31(33):4199-4206.
［11］Westin JR,Chu F,Zhang MS,et al.Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma:a single group,open-label,phase 2 trial ［J］.Lancet Oncol,2014,15(1):69-77.
［12］Li Y,Wang J,Ke XY.Expression of PD-L1 in lymphoma and its effect on lymphoma proliferation and chemotherapy resistance ［J］.J Experimental Hematol,2013,21(1):366-370.［李义,王晶,克晓燕.PD-L1在淋巴瘤中的表达及其对淋巴瘤增殖和化疗抵抗的初步研究［J］.中国实验血液学杂志,2013,21(1):366-370.］
［13］Lv XW,Wang B,Li YQ.The change of CD45RA+ and CD45RO+ T cell in peripheral blood in peripheral T-cell lymphoma patients before and after CHOP chemotherapy ［J］.Chin J Immunol,2015,31(4):121-124.［吕学文，王博，李扬秋.CHOP方案治疗前后外周T细胞淋巴瘤患者外周血CD45RA+T和CD45RO+T的变化特点［J］.中国免疫学杂志，2015,31（4）：121-124.］
［14］Han LJ,Zhang MZ.The expression and immune modulating function of PD-L1 and PD-1 in extra nodal NK/T cell［D］.Zhengzhou:the First Affiliated Hospital of Zhengzhou University,2014:1-49.［韩丽娟，张明智.PD-L1及其受体PD-1在结外NK/T细胞淋巴瘤中的表达及免疫调节功能［D］.郑州：郑州大学第一附属医院,2014:1-49.］
［15］Wohman AM，van der Kooij SW，de Fijter JW，et al．Maturation resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations［J］．Am J Transplant，2006，6(11):2580-2591．

Memo

Memo:
广东省医学科学技术研究基金项目（编号：B2015039）
Last Update: 2017-04-01